Here are five things to know:
1. Researchers implanted MagnetOs Granules and MagnetOs Putty into 25 adult female Merino sheep who underwent posterolateral spinal fusion at L2-3 and L4-5 levels with instrumentation.
2. The study authors assessed outcomes at six-, 12- and 26-weeks postoperatively. At 12-weeks postoperatively, researchers found 100 percent fusion rates in all treatment groups.
3. The three treatment groups showed a statistically significant decrease in lateral bending at the fusion levels at 12-weeks and 26-weeks compared to six-weeks postoperatively, which further confirmed spinal fusion success.
4. Histological assessment at 12-weeks postoperatively demonstrated a 75 percent fusion rate for autograft, 92 percent fusion rate for MagnetOs Granules and 83 percent fusion rate for MagnetOs Putty. Fusion rates further increased at 26-weeks post-implantation.
5. The researchers did not observe any significant differences in range of motion between the treatment groups at any time.
More articles on biologics:
5 things to know about Carmell Therapeutics
Global spinal biologics market to exceed $2.36B by 2021: 3 findings
Anika Therapeutics resumes distribution of cartilage regeneration treatments
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
